Drug intelligence / Profile preview

MEG321

Development stage: Preclinical
Lead developer: Medley Therapeutics

Overview

MEG321 is an advanced biologic candidate currently in the discovery phase for the treatment of renal disease. It is being developed by Medley Therapeutics (formerly YAP Therapeutics) as part of their Advanced Biologics platform, which focuses on addressing fibrosis and solid tumor cancers. While the specific molecular target and mechanism of action for MEG321 have not been publicly disclosed, the candidate is categorized within the company's fibrosis therapeutic area, suggesting a potential application in mitigating renal fibrosis.

Beyond the preview

Go deeper on MEG321.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEG321.

Explore the full profile